Bone and soft-tissue sarcomas originate from mesenchymal tissues that include bone, cartilage, muscles, fat, fibrous tissues, vessels, and peripheral nerves. Bone and soft-tissue sarcomas are rare disease, accounting for less than 1% of all malignancies, and there are 50 different types of sarcomas. Sarcomas show characteristic differences in cell of origin, disease site, growth tendency, and chemosensitivity. Biomarkers can be integrated into clinical practice to improve diagnostic accuracy, predict treatment response, and optimize the therapeutic strategy of sarcomas. We aimed to identify the novel biomarkers for several types of sarcomas using proteomic approach. The protein expression profiles of sarcomas were created using two-dimensional difference gel electrophoresis (2D-DIGE). Protein samples were labeled by CyDye DIGE Fluor saturation dye and separated by our original large format gels. The reproducible proteome data were obtained by using internal control samples. Proteomic study identified biomarker candidates for personalized therapy of sarcoma patients. Using 2D-DIGE and sarcoma clinical specimens with a detailed clinicopathological dataset, we identified proteins that influenced metastasis / recurrence after surgery in gastrointestinal stromal tumor (GIST) patients, or those induced resistance to standard chemotherapy in osteosarcoma patients. These biomarkers may be a useful clinical tool to develop personalized therapeutic strategies in bone and soft-tissue sarcoma patients.
View full abstract